Lab-grown mini-tumours are already being sold to guide treatment, but the tests are not validated like other medical tests. They should be.
Functional drug-response assays are entering clinical use without the analytical validation (precision, repeatability, reference ranges, failure rate reporting) or clinical validation (prospective outcome correlation) required of companion diagnostics. The proposal is a formal assay validation framework, developed with regulators, defining minimum performance, standardised reporting of derivation success rate, and mandatory registry submission of predictions and outcomes.
Shares Curesponse, Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Curesponse, SEngine Precision Medicine, Xilis, Ex vivo drug sensitivity screening in blood cancers (EXALT).
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Xilis, Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Estimation of clinical trial success rates and related parameters, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients, Patient-derived organoids.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients, Patient-derived organoids.
Shares Estimation of clinical trial success rates and related parameters, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients, Patient-derived organoids.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/